Alixia
Alixia is focused on targeting the tumor ecosystem to address cancer drug resistance and improve patients' lives. They study the interactions within the tumor ecosystem, integrating biology, biophysics, computational chemistry, and clinical input to develop new therapeutic innovations. Their approach involves disrupting the metabolic and inflammatory triggers in cancer and quasi-cancerous cells to enable effective, lasting cancer treatment. The company is also developing new modalities to treat complex, chronic diseases related to cancer, aging, and immunity.
Industries
Nr. of Employees
small (1-50)
Products
Tumor ecosystem disruptor candidates (preclinical)
Lead compounds developed to disrupt metabolic and inflammatory triggers across cancer and quasi-cancerous cells in the tumor microenvironment; programs are at preclinical stages and address solid tumors and age-related diseases.
Tumor ecosystem disruptor candidates (preclinical)
Lead compounds developed to disrupt metabolic and inflammatory triggers across cancer and quasi-cancerous cells in the tumor microenvironment; programs are at preclinical stages and address solid tumors and age-related diseases.
Services
A multidisciplinary discovery capability that combines biology, biophysics, computational chemistry and clinical collaboration to identify molecules that modulate tumor microenvironments.
A multidisciplinary discovery capability that combines biology, biophysics, computational chemistry and clinical collaboration to identify molecules that modulate tumor microenvironments.
Expertise Areas
- Tumor microenvironment research
- Ecosystem-targeted drug discovery
- Preclinical therapeutic development
- Computational tumor modeling
Key Technologies
- Computational chemistry
- Computational tumor modeling / digital tumor landscapes
- Biophysical characterization of tissue (stiffness, mechanical stress)
- Multicellular in vitro screening assays